{"id":456,"date":"2019-06-11T13:16:32","date_gmt":"2019-06-11T04:16:32","guid":{"rendered":"https:\/\/info.zanet.biz\/?p=456"},"modified":"2019-06-26T09:15:19","modified_gmt":"2019-06-26T00:15:19","slug":"multi-criteria-decision-analysis-mcda%e3%81%ae%e3%82%b9%e3%83%86%e3%83%83%e3%83%97","status":"publish","type":"post","link":"https:\/\/info.zanet.biz\/?p=456","title":{"rendered":"Multi-Criteria Decision Analysis (MCDA)\u306e\u30b9\u30c6\u30c3\u30d7"},"content":{"rendered":"\n

International Society for Pharmacoeconomics and Outcomes Research (ISPOR) \u56fd\u969b\u533b\u85ac\u7d4c\u6e08\u30fb\u30a2\u30a6\u30c8\u30ab\u30e0\u7814\u7a76\u5b66\u4f1a\u306e ISPOR MCDA Emerging Good Practices Task Force\u304cMCDA\u306b\u95a2\u3059\u308b\u30ac\u30a4\u30c0\u30f3\u30b9\u3092Report 1<\/a>\u304a\u3088\u3073Report 2<\/a>\u3068\u3057\u30662016\u5e74\u306b\u767a\u8868\u3057\u3066\u3044\u307e\u3059\u3002<\/p>\n\n\n\n

Steps in a value measurement MCDA process \u3068\u3057\u30668\u3064\u306e\u30b9\u30c6\u30c3\u30d7\u304c\u6319\u3052\u3089\u308c\u3066\u3044\u307e\u3059\u3002Value measurement\u3068\u3044\u3046\u8a00\u8449\u304c\u7528\u3044\u3089\u308c\u3001\u85ac\u7269\u7642\u6cd5\u306e\u4fa1\u5024\u3092\u5b9a\u91cf\u7684\u306b\u8a55\u4fa1\u3059\u308b\u3068\u3044\u3046\u610f\u5473\u3060\u3068\u601d\u308f\u308c\u307e\u3059\u3002<\/p>\n\n\n\n

1.Defining the decision problem
2.Selecting and structuring criteria
3.Measuring performance
4.Scoring alternatives
5.Weighting criteria
6.Calculating aggregate scores
7.Dealing with uncertainty
8.Reporting and examination of findings <\/p>\n\n\n\n

Report 2\u3067\u306f\u3053\u308c\u3089\u306b\u57fa\u3065\u3044\u305f\u30c1\u30a7\u30c3\u30af\u30ea\u30b9\u30c8\u3082\u63b2\u8f09\u3055\u308c\u3066\u3044\u307e\u3059\u3002<\/p>\n\n\n\n

\u8a3a\u7642\u30ac\u30a4\u30c9\u30e9\u30a4\u30f3\u4f5c\u6210\u306e\u30d7\u30ed\u30bb\u30b9\u306b\u304a\u3051\u308b\u30b9\u30c6\u30c3\u30d7\u3092\u3053\u308c\u3089\u306b\u5bfe\u5fdc\u3057\u3066\u30ea\u30b9\u30c8\u30a2\u30c3\u30d7\u3059\u308b\u3068\u6b21\u306e\u69d8\u306b\u306a\u308b\u3068\u601d\u3044\u307e\u3059\u3002\uff08\u3053\u308c\u306f\u3001\u8457\u8005\u304c\u4f5c\u6210\u3057\u305f\u3082\u306e\u3067\u3059\u3002\uff09<\/p>\n\n\n\n

1.Finding KCI and formulating CQ
2.Setting outcomes
3.Calculating effect estimates with SR
4.Comparing absolute effects
5.Setting importance of outcomes
6.Evaluating benefits and harms
7.Doing sensitivity analysis
8.Developing SoF and EtD framework with graphs

* KCI: Key Clinical Issue, CQ: Clilnical Question, SR: Systematic Review, SoF: Summary of Findings, EtD: Evidence-to-Decision . SoF\u3001EtD\u306fGrading of Recommendations, Assessment, Development and Evaluation (GRADE) approach<\/a>\u306b\u57fa\u3065\u304f\u30b9\u30c6\u30c3\u30d7\u3067\u3059\u3002<\/p>\n\n\n\n

\u540c\u3058\u6982\u5ff5\u3092\u7570\u306a\u308b\u8a00\u8449\u3067\u8868\u73fe\u3057\u3066\u3044\u308b\u305f\u3081\u3001\u7570\u306a\u308b\u4f5c\u696d\u306e\u3088\u3046\u306b\u307f\u3048\u307e\u3059\u304c\u3001\u5b9f\u969b\u306b\u306f\u540c\u3058\u4f5c\u696d\u306e\u3082\u306e\u304c\u591a\u3044\u3067\u3059\u3002\u3057\u304b\u3057\u30014\u306escoring\u3068absolute effects\u306f\u540c\u3058\u3067\u306f\u3042\u308a\u307e\u305b\u3093\u30026\u306eaggregate scores\u306e\u8a08\u7b97\u3068\u5358\u306a\u308bbenefit-harm\u306e\u8a55\u4fa1\u3082\u9055\u3044\u307e\u3059\u3002<\/p>\n\n\n\n

\u6700\u8fd1GRADE concept paper\u3068\u3057\u3066Defining certainty of net benefit\u3068\u3044\u3046\u8ad6\u6587<\/a>\u304c\u767a\u8868\u3055\u308c\u3066\u3044\u307e\u3059\u3002\u3053\u306e\u4e2d\u3067\u3001\u30a2\u30e1\u30ea\u30abUSPSTF\u306e”certainty of net benefit”\u306e\u3053\u3068\u3082\u5f15\u7528\u3055\u308c\u3066\u3044\u307e\u3059\u3057\u3001\u30a4\u30ae\u30ea\u30b9NICE\u306eDecision Analylsis\u306e\u6d3b\u7528\u306b\u3064\u3044\u3066\u3082\u89e6\u308c\u3089\u308c\u3066\u304a\u308a\u3001GRADE working group\u3082Decision modelling\u3084Decision analysis\u306b\u3064\u3044\u3066\u691c\u8a0e\u4e2d\u3067\u3042\u308b\u3068\u8ff0\u3079\u3066\u3044\u307e\u3059\u3002\u305f\u3060\u3057\u3001ISPOR\u306e\u8ad6\u6587\u306f\u5f15\u7528\u3055\u308c\u3066\u3044\u307e\u305b\u3093\u3002\u3053\u306e\u8ad6\u6587\u3067”A stepwise approach to determining the certainty of the net effect estimate”\u3067\u306f\u4ee5\u4e0b\u306e\u30b9\u30c6\u30c3\u30d7\u304c\u8a18\u8ff0\u3055\u308c\u3066\u3044\u307e\u3059\u3002<\/p>\n\n\n\n

1.Determine the outcomes to be combined.
2.Determine the quantified relative importance for each outcome.
3.Combine the importance-adjusted effect estimates.
4.Classify the precision of the net effect estimate.
5.Consider the certainty of effect estimates for outcomes that are critical to the likelihood of net benefit.
6.Determine if certainty of net benefit changes across a reasonable range of relative importance.<\/p>\n\n\n\n

USPSTF\u306e\u63a8\u5968Grade<\/a>\u306b\u3064\u3044\u3066\u306f\u3053\u306e\u8ad6\u6587\u3067\u3082\u53d6\u308a\u4e0a\u3052\u3089\u308c\u3066\u3044\u307e\u3059\u304c\u3001MCDA\u3068\u3044\u3046\u8a00\u8449\u306f\u51fa\u3066\u304d\u307e\u305b\u3093\u3002\u3057\u304b\u3057\u3001\u8907\u6570\u306e\u76ca\u3068\u5bb3\u306e\u30a2\u30a6\u30c8\u30ab\u30e0\u306b\u5bfe\u3059\u308b\u4ecb\u5165\u306e\u52b9\u679c\u3092\u5168\u4f53\u3068\u3057\u3066\u5b9a\u91cf\u7684\u306b\u8a55\u4fa1\u3059\u308b\u3053\u3068\u306fMCDA\u305d\u306e\u3082\u306e\u3067\u3059\u3002<\/p>\n\n\n\n

Appendix\u3068\u3057\u3066\u3001\u5b9f\u4f8b\u3068net effect estimate\u306e\u8a08\u7b97\u6cd5\u304c\u7d39\u4ecb\u3055\u308c\u3066\u3044\u307e\u3059\u304c\u3001\u52b9\u679c\u63a8\u5b9a\u5024\u306f”are expressed using the same units of measure”\u305d\u3057\u3066\u3001”are independent and not correlated with each other”\u3068\u5236\u9650\u304c\u3064\u3051\u3089\u308c\u3066\u3044\u307e\u3059\u3002\u4fa1\u5024\u95a2\u6570\u3068\u3044\u3046\u8003\u3048\u306f\u53d6\u308a\u5165\u308c\u3089\u308c\u3066\u3044\u307e\u305b\u3093\u3002<\/p>\n\n\n\n

\u307e\u305f\u3001”Classification of precision of net effect estimate”\u3067\u306fNet benefit, Likely net benefit, Possible net benefit, Possibly no net benefit or harm, Net benefit or harm likely near zero, Possible net harm, Likely net harm, Net harm\u306b\u5206\u985e\u3057\u3066\u3044\u307e\u3059\u3002\u305d\u308c\u305e\u308c\u304c\u3001High certainty of net benefit, Moderate certainty of net benefit, Low certainty of net benefit, Very low certainty of net benefit or harm, Moderate certainty of little net benefit or harm, Low certainty of net harm, Moderate certainty of net harm, High certainty of net harm\u306b\u5bfe\u5fdc\u3059\u308b\u305d\u3046\u3067\u3059\u3002 <\/p>\n\n\n\n

References:
1. Thokala P, Devlin N, Marsh K, Baltussen R, Boysen M, Kalo Z, Longrenn T, Mussen F, Peacock S, Watkins J, Ijzerman M: Multiple Criteria Decision Analysis for Health Care Decision Making–An Introduction: Report 1 of the ISPOR MCDA Emerging Good Practices Task Force. Value Health 2016;19:1-13. PMID: 26797229<\/a>
2. Marsh K, IJzerman M, Thokala P, Baltussen R, Boysen M, Kal\u00f3 Z, L\u00f6nngren T, Mussen F, Peacock S, Watkins J, Devlin N, ISPOR Task Force: Multiple Criteria Decision Analysis for Health Care Decision Making–Emerging Good Practices: Report 2 of the ISPOR MCDA Emerging Good Practices Task Force. Value Health 2016;19:125-37. PMID: 27021745 <\/a>
3.Alper BS, Oettgen P, Kunnamo I, Iorio A, Ansari MT, Murad MH, Meerpohl JJ, Qaseem A, Hultcrantz M, Sch\u00fcnemann HJ, Guyatt G, GRADE Working Group: Defining certainty of net benefit: a GRADE concept paper. BMJ Open 2019;9:e027445. PMID: 31167868<\/a>
<\/p>\n","protected":false},"excerpt":{"rendered":"

International Society for Pharmacoeconomics and Outcomes Research (ISPOR) \u56fd\u969b\u533b\u85ac\u7d4c\u6e08\u30fb\u30a2\u30a6\u30c8\u30ab\u30e0\u7814\u7a76\u5b66\u4f1a\u306e ISPOR MCDA Em … “Multi-Criteria Decision Analysis (MCDA)\u306e\u30b9\u30c6\u30c3\u30d7” \u306e<\/span>\u7d9a\u304d\u3092\u8aad\u3080<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[27,5,3],"tags":[],"class_list":["post-456","post","type-post","status-publish","format-standard","hentry","category-benefit-harm-assessment","category-cpg","category-mdm"],"_links":{"self":[{"href":"https:\/\/info.zanet.biz\/index.php?rest_route=\/wp\/v2\/posts\/456","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/info.zanet.biz\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/info.zanet.biz\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/info.zanet.biz\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/info.zanet.biz\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=456"}],"version-history":[{"count":7,"href":"https:\/\/info.zanet.biz\/index.php?rest_route=\/wp\/v2\/posts\/456\/revisions"}],"predecessor-version":[{"id":551,"href":"https:\/\/info.zanet.biz\/index.php?rest_route=\/wp\/v2\/posts\/456\/revisions\/551"}],"wp:attachment":[{"href":"https:\/\/info.zanet.biz\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=456"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/info.zanet.biz\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=456"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/info.zanet.biz\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=456"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}